Electroporation improves the efficacy of DNA vaccines in large animals

被引:144
作者
Babiuk, S
Baca-Estrada, ME
Foldvari, M
Storms, M
Rabussay, D
Widera, G
Babiuk, LA
机构
[1] Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada
[2] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada
基金
加拿大健康研究院;
关键词
in vivo electroporation; multiple antigens; intramuscular DNA vaccination;
D O I
10.1016/S0264-410X(02)00269-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It is generally recognized that DNA vaccines are often less effective in large animals than in mice. One possible reason for this reduced effectiveness may be transfection efficiency and the low level of expression elicited by plasmid vectors in large animals. A possible way to improve plasmid gene expression in vivo is electroporation. To determine whether we could enhance immune responses in pigs by electroporation, we used plasmids encoding two different genes (bovine herpesvirus glycoprotein D (gD) and hepatitis B surface antigen (HBsAg)) and two different electrodes, a single-needle electrode and a six-needle electrode. Electroporation significantly enhanced immune responses to both antigens. In addition, we demonstrated that co-administration of plasmids coding for two different antigens (pgD and pHBsAg) did not result in significant interference between the plasmids. We also incorporated a DNA prime/protein boost strategy to examine the effect of DNA priming with electroporation on the immune response after a protein boost. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3399 / 3408
页数:10
相关论文
共 35 条
[1]   Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: Effect of antigen form on the induction of cellular and humoral immune responses [J].
BacaEstrada, ME ;
Snider, M ;
Tikoo, SK ;
Harland, R ;
Babiuk, LA ;
LittelVandenHurk, SV .
VIRAL IMMUNOLOGY, 1996, 9 (01) :11-22
[2]   Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants [J].
Benne, CA ;
Harmsen, M ;
vanderGraaff, W ;
Verheul, AFM ;
Snippe, H ;
Kraaijeveld, CA .
VACCINE, 1997, 15 (09) :1039-1044
[3]   Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation [J].
Braun, R ;
Babiuk, LA ;
Littel-van den Hurk, SV .
JOURNAL OF GENERAL VIROLOGY, 1998, 79 :2965-2970
[4]   DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines [J].
Davis, HL ;
McCluskie, MJ ;
Gerin, JL ;
Purcell, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :7213-7218
[5]   Efficient nonviral cutaneous transfection [J].
Glasspool-Malone, J ;
Somiari, S ;
Drabick, JJ ;
Malone, RW .
MOLECULAR THERAPY, 2000, 2 (02) :140-146
[6]   Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation [J].
Heller, R ;
Schultz, J ;
Lucas, ML ;
Jaroszeski, MJ ;
Heller, LC ;
Gilbert, RA ;
Moelling, K ;
Nicolau, C .
DNA AND CELL BIOLOGY, 2001, 20 (01) :21-26
[7]   PROTECTION AGAINST MALARIA BY IMMUNIZATION WITH A PLASMODIUM-YOELII CIRCUMSPOROZOITE PROTEIN NUCLEIC-ACID VACCINE [J].
HOFFMAN, SL ;
SEDEGAH, M ;
HEDSTROM, RC .
VACCINE, 1994, 12 (16) :1529-1533
[8]   Electroporation therapy: A new approach for the treatment of head and neck cancer [J].
Hofmann, GA ;
Dev, SB ;
Dimmer, S ;
Nanda, GS .
IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 1999, 46 (06) :752-759
[9]   Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen [J].
Jones, TR ;
Narum, DL ;
Gozalo, AS ;
Aguiar, J ;
Fuhrmann, SR ;
Liang, H ;
Haynes, JD ;
Moch, JK ;
Lucas, C ;
Luu, T ;
Magill, AJ ;
Hoffman, SL ;
Sim, BKL .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (02) :303-312
[10]   A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene [J].
Kotsopoulou, E ;
Kim, VN ;
Kingsman, AJ ;
Kingsman, SM ;
Mitrophanous, KA .
JOURNAL OF VIROLOGY, 2000, 74 (10) :4839-4852